A novel blood test analyzing fragments of cell-free DNA showed robust diagnostic performance for colorectal cancer across clinical subgroups, offering a promising noninvasive screening method.

A groundbreaking study introduces new noninvasive screening tools that have the potential to greatly enhance patient comfort ...

Dear Dr. Roach: I am 85 and healthy apart from polycythemia vera, for which I take aspirin. I was interested in the new blood test for cancer. Is it worthwhile? Dear M.N.: When screening patients for ...

DEAR DR. ROACH: I am 85 and healthy apart from polycythemia vera, for which I take aspirin. I was interested in the new blood test for cancer. Is it worthwhile? -- M.N. ANSWER: When screening patients ...

Researchers combined protein biomarkers, cfDNA analysis, and machine learning to open opportunities for early-stage ovarian cancer screening and diagnostics. The cfDNA fragmentome is a genome-wide ...

A new cfDNA-based blood test uses AI to detect bladder, prostate, and kidney cancers early, offering a faster, safer, and ...

Galleri is a blood test that aims to detect over 50 types of cancer early. It analyzes cell-free DNA (cfDNA) and methylation patterns to identify potential cancer signals. The test is intended for ...

An Austin, Texas-based genetics-testing company that specializes in cell-free DNA and precision medicine has acquired Foresight Diagnostics Inc., a Boulder-based cancer-diagnostics company.

*Refers to the latest 2 years of stltoday.com stories. Cancel anytime. Dr. Roach: I am 85 and healthy apart from polycythemia vera, for which I take aspirin. I was interested in the new blood test for ...